Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 3,236 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,236 shares of the firm’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the transaction, the insider now directly owns 170,285 shares of the company’s stock, valued at $4,728,814.45. The trade was a 1.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.30, for a total value of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.

Hims & Hers Health Trading Up 5.0 %

Shares of NYSE HIMS traded up $1.49 during mid-day trading on Tuesday, reaching $31.04. 45,978,327 shares of the company’s stock were exchanged, compared to its average volume of 14,436,744. The firm has a market capitalization of $6.90 billion, a price-to-earnings ratio of 70.54 and a beta of 1.37. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The business has a fifty day simple moving average of $39.92 and a 200 day simple moving average of $29.67.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Needham & Company LLC upped their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $37.31.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the company. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter worth $28,000. Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health during the 4th quarter valued at approximately $38,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.